What caused the intraday drop in BION.SW stock today?

The intraday drop to **CHF 42.70** reflects sector-wide profit taking in biotech, lower risk appetite, and position trimming after recent gains. Volume was **68,584** shares, signaling focused selling rather than broad liquidation.

Is BION.SW stock a value buy after the decline?

Valuation metrics are cheap: **PE 4.07** and price-to-book **0.84**, with dividend yield **5.25%**. However, negative return ratios and portfolio volatility mean investors should weigh risk tolerance and use position sizing.

What price targets and forecasts exist for BION.SW stock?

Meyka AI's forecast model projects a **yearly price CHF 42.56** and a **3-year target CHF 45.74**. These are model-based projections and not guarantees; they should be used with other research.

How does sector performance affect BION.SW stock trading?

Switzerland healthcare is down **-8.0%** YTD, which increases downside pressure on BB Biotech. Sector weakness often amplifies moves in portfolio funds like BION.SW, making macro and sector news critical.

CH Stocks

BION.SW down 5.95% to CHF42.70 on SIX 24 Mar 2026: Will dividend hold

ByHuzaifa Zahoor March 24, 2026March 24, 2026

BION.SW stock opened the intraday session lower and is trading at CHF 42.70, down 5.95% as of 24 Mar 2026 on the SIX exchange in Switzerland. The move follows weaker market sentiment in healthcare names and profit taking after a recent run. Price fell from an opening CHF 43.00 to a day low of CHF 42.25 on volume of 68,584 shares. Investors are watching valuation metrics and the 5.25% dividend yield as short-term support while dividend sustainability and portfolio holdings drive next moves.